Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YAP1 | P46937 | 3/20 | 0.51 |
| ▸ | PRMT5 | O14744 | 7/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.43 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27715096 | 1.00 | YAP1 (0.51) | YAP1PRMT5GPR119JAK2JAK1 | |
| SCHEMBL27715065 | 0.99 | YAP1 (0.50) | YAP1PRMT5GPR119JAK2JAK1 | |
| SCHEMBL4476703 | 0.91 | JAK2 (0.49) | GPR119JAK2JAK1ABHD6DAGLA | |
| SCHEMBL27715171 | 0.89 | EPHA2 (0.48) | YAP1GPR119LMNA | |
| SCHEMBL1552451 | 0.88 | GPR119 (0.47) | GPR119LMNA | |
| SCHEMBL27715095 | 0.88 | GPR119 (0.47) | GPR119LMNA | |
| SCHEMBL1552953 | 0.85 | ALDH1A1 (0.48) | GPR119LMNA | |
| SCHEMBL1552058 | 0.85 | ALDH1A1 (0.48) | GPR119LMNA | |
| SCHEMBL1551948 | 0.85 | USP2 (0.43) | GPR119JAK2JAK1 | |
| SCHEMBL1551950 | 0.85 | USP2 (0.43) | GPR119JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844026-B1 | MORPHOLINES AS 5HT2C AGONISTS | HOFFMANN LA ROCHE (CH) | 2011-04-27 | — | — | EP | disclosed |
| EP-1844026-B1 | MORPHOLINES AS 5HT2C AGONISTS | HOFFMANN LA ROCHE (CH) | 2011-04-27 | — | — | EP | disclosed |
| CN-101107235-B | Morpholines as 5HT2C agonists | HOFFMANN LA ROCHE | 2011-03-16 | — | — | CN | disclosed |
| US-7323466-B2 | Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HOFFMAN-LA ROCHE INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323466-B2 | Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HOFFMAN-LA ROCHE INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323466-B2 | Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HOFFMAN-LA ROCHE INC. (US) | 2008-01-29 | — | — | US | disclosed |
| CN-101107235-A | Morpholines as 5HT2C agonists | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | CN | disclosed |
| EP-1844026-A2 | MORPHOLINES AS 5HT2C AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| US-20060178510-A1 | New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HOFFMANN-LA ROCHE INC. | 2006-08-10 | — | — | US | disclosed |
| WO-2006077025-A2 | MORPHOLINES AS 5HT2C AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178510-A1 | New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HTR2C, HTR1A, HTR1B | YAP1 4012/4885PRMT5 810/4885GPR119 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.